<DOC>
	<DOCNO>NCT02398747</DOCNO>
	<brief_summary>The primary objective study investigate safety tolerability continuous and/or intermittent dose AZD2014 give orally patient advance solid malignancy .</brief_summary>
	<brief_title>Japanese Phase I Study AZD2014 Advanced Solid Malignancies</brief_title>
	<detailed_description>This open-label , multi-centre study AZD2014 administer orally Japanese patient advance solid malignancy . The study design allow evaluation cohort intensive safety monitoring ensure safety patient . In study , minimum 3 maximum 6 evaluable patient enrol cohort ; approximately 24 evaluable patient total . The total number patient enrol depend upon number screen failure , number cohort number evaluable subject . Safety , preliminary efficacy PK ( single multiple dose ) evaluate study . Patients receive single dose AZD2014 Day 1 ( allow assessment single dose PK ) , minimum 48 hour washout period continuous intermittent twice daily dose AZD2014 initiate . The washout period 48 hour may extend depend emerge data previous cohorts.Doses schedule evaluate agree AstraZeneca Safety Review Committee ( SRC ) .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Histological cytological confirmation solid , malignant tumour refractory standard therapy standard therapy exist For Cohort 31 32 , follow , Histological cytological confirmation solid , malignant tumour refractory standard therapy standard therapy exist treatment paclitaxel appropriate treatment option . SqNSCLC patient exclude Cohort 32 . World Health Organisation ( WHO ) performance status ( PS ) 01 deterioration previous 2 week prior inform consent minimum life expectancy 12 week At least one lesion accurately assess baseline compute tomography ( CT ) magnetic resonance imaging ( MRI ) plain Xray suitable repeat assessment Exclusion Criteria Prior chemotherapy , biological therapy , radiation therapy , antiandrogens , anticancer therapy include immunotherapy investigational agent within 21 day start study treatment ( include palliative radiotherapy focal site ) , corticosteroid within 14 day start study treatment . Major surgery within 4 week prior study treatment ( exclude placement vascular access ) , minor surgery within 2 week prior study treatment Potent moderate inhibitor inducer cytochrome ( CYP ) 3A4/5 take within state washout period : Potent moderate inhibitor inducer CYP2C8 take within state washout period : Exposure sensitive narrow therapeutic range substrate drug metabolise enzyme CYP2C8 , CYP2C9 , CYP2C19 , CYP2D6 drug transporter Pgp ( MDR1 ) , Breast cancer resistance protein ( BCRP ) , Organic anion transport polypeptide ( OATP ) 1B1 , OATP1B3 , Organic cation transporter ( OCT ) 1 OCT2 within appropriate washout period ( least 5 x report terminal elimination halflife ( t1/2 ) drug ) study treatment . Any haemopoietic growth factor ( eg , granulocytecolony stimulate factor [ GCSF ] ) within 2 week prior receive study drug Previous initiation treatment AZD2014 present study prior treatment AZD8055 With exception alopecia , unresolved toxicity prior chemotherapy great Common toxicity criterion adverse event ( CTCAE ) grade 1 time start study treatment Spinal cord brain metastasis unless asymptomatic stable steroid least 4 week prior start study treatment Subjects interstitial lung disease complication history</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>